JUNO THERAPEUTICS, INC. (JUNO) financial statements (2021 and earlier)

Company profile

Business Address 400 DEXTER AVENUE NORTH, SUITE 1200
SEATTLE, WA 98109
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments726733943
Cash and cash equivalents233188252
Short-term investments493545691
Receivables1413 
Other undisclosed current assets13268
Total current assets:753772952
Noncurrent Assets
Property, plant and equipment1338242
Long-term investments and receivables248190273
Long-term investments248190273
Intangible assets, net (including goodwill)297299172
Goodwill221221122
Intangible assets, net (excluding goodwill)757850
Other noncurrent assets466
Total noncurrent assets:681577493
TOTAL ASSETS:1,4351,3491,445
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities944138
Accounts payable1244
Accrued liabilities813733
Business combination, contingent consideration, liability282
Deferred revenue and credits214315
Other undisclosed current liabilities922365
Total current liabilities:209115120
Noncurrent Liabilities
Long-term debt and lease obligation10  
Long-term debt, excluding current maturities10  
Liabilities, other than long-term debt123157175
Deferred revenue and credits100120130
Deferred tax liabilities, net 59
Other liabilities 180
Business combination, contingent consideration, liability231335
Total noncurrent liabilities:133157175
Total liabilities:341272294
Stockholders' equity
Stockholders' equity attributable to parent1,0471,0781,142
Common stock000
Additional paid in capital2,3121,9121,733
Accumulated other comprehensive income (loss)3(3)(6)
Accumulated deficit(1,268)(831)(586)
Total stockholders' equity:1,0471,0781,142
Other undisclosed liabilities and equity46 9
TOTAL LIABILITIES AND EQUITY:1,4351,3491,445

Income statement (P&L) ($ in millions)

12/31/2017
12/31/2016
12/31/2015
Gross profit:1127918
Operating expenses(560)(335)(262)
Operating loss:(448)(256)(244)
Nonoperating income (expense)(4)(7)0
Investment income, nonoperating (5) 
Other nonoperating income (expense)(4)(1)0
Other undisclosed income from continuing operations before equity method investments, income taxes86 
Loss from continuing operations before equity method investments, income taxes:(443)(256)(244)
Other undisclosed income from continuing operations before income taxes  2
Loss from continuing operations before income taxes:(443)(256)(242)
Income tax benefit6113
Net loss available to common stockholders, diluted:(437)(246)(239)

Comprehensive Income ($ in millions)

12/31/2017
12/31/2016
12/31/2015
Net loss:(437)(246)(239)
Other comprehensive income (loss)63(6)
Comprehensive loss, net of tax, attributable to parent:(431)(242)(245)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: